Yejin Mok1, Heejin Kimm2, Sang Yop Shin3, Sun Ha Jee4, Elizabeth A Platz5. 1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Department of Epidemiology and Health Promotion and Institute for Health Promotion, Graduate School of Public Health, Yonsei University, Seoul, Korea. 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. 3. Korea Medical Institute, Seoul, Korea. 4. Department of Epidemiology and Health Promotion and Institute for Health Promotion, Graduate School of Public Health, Yonsei University, Seoul, Korea. Electronic address: jsunha@yuhs.ac. 5. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
Abstract
OBJECTIVE: To evaluate the association between serum prostate-specific antigen (PSA) concentration from a screening test and prostate cancer mortality in an Asian population. METHODS: We included 118,665 men in the Korean Heart Study, a large prospective cohort study of participants who voluntarily underwent private health examinations that included PSA-based prostate cancer screening. The baseline visit occurred between January 1994 and December 2004, and follow-up was through December 2011. Deaths from prostate cancer were ascertained from the underlying cause of death from a computerized search of death certificate data from the National Statistical Office in Korea. We used the Cox proportional hazards regression to estimate the association between serum PSA and risk of prostate cancer death adjusting the baseline age, cigarette smoking status, and body mass index. RESULTS: During 1,381,901 person-years of follow-up, 6036 men died of any cause, and of these, 56 men died of prostate cancer. The multivariate-adjusted hazard ratio for prostate cancer death statistically significantly increased across PSA concentrations (P trend <.0001). The hazard ratio increased 7% per 1-ng/mL increase in PSA. The association between PSA concentration and death from prostate cancer was stronger in younger than in older men and in heavier than leaner men. CONCLUSION: In conclusion, an increased screening PSA level is associated with an increased risk of prostate cancer death in Korean men. Our findings may have implications for the development of targeted PSA cutpoints for biopsy recommendation.
OBJECTIVE: To evaluate the association between serum prostate-specific antigen (PSA) concentration from a screening test and prostate cancer mortality in an Asian population. METHODS: We included 118,665 men in the Korean Heart Study, a large prospective cohort study of participants who voluntarily underwent private health examinations that included PSA-based prostate cancer screening. The baseline visit occurred between January 1994 and December 2004, and follow-up was through December 2011. Deaths from prostate cancer were ascertained from the underlying cause of death from a computerized search of death certificate data from the National Statistical Office in Korea. We used the Cox proportional hazards regression to estimate the association between serum PSA and risk of prostate cancer death adjusting the baseline age, cigarette smoking status, and body mass index. RESULTS: During 1,381,901 person-years of follow-up, 6036 men died of any cause, and of these, 56 men died of prostate cancer. The multivariate-adjusted hazard ratio for prostate cancer death statistically significantly increased across PSA concentrations (P trend <.0001). The hazard ratio increased 7% per 1-ng/mL increase in PSA. The association between PSA concentration and death from prostate cancer was stronger in younger than in older men and in heavier than leaner men. CONCLUSION: In conclusion, an increased screening PSA level is associated with an increased risk of prostate cancer death in Korean men. Our findings may have implications for the development of targeted PSA cutpoints for biopsy recommendation.
Authors: H Ballentine Carter; E Jeffrey Metter; James Wright; Patricia Landis; Elizabeth Platz; Patrick C Walsh Journal: J Natl Cancer Inst Date: 2004-04-07 Impact factor: 13.506
Authors: H Ballentine Carter; Peter C Albertsen; Michael J Barry; Ruth Etzioni; Stephen J Freedland; Kirsten Lynn Greene; Lars Holmberg; Philip Kantoff; Badrinath R Konety; Mohammad Hassan Murad; David F Penson; Anthony L Zietman Journal: J Urol Date: 2013-05-06 Impact factor: 7.450
Authors: Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg Journal: N Engl J Med Date: 2009-03-18 Impact factor: 91.245
Authors: Ruth Etzioni; Alex Tsodikov; Angela Mariotto; Aniko Szabo; Seth Falcon; Jake Wegelin; Dante DiTommaso; Kent Karnofski; Roman Gulati; David F Penson; Eric Feuer Journal: Cancer Causes Control Date: 2007-11-20 Impact factor: 2.506
Authors: Brenda K Edwards; Anne-Michelle Noone; Angela B Mariotto; Edgar P Simard; Francis P Boscoe; S Jane Henley; Ahmedin Jemal; Hyunsoon Cho; Robert N Anderson; Betsy A Kohler; Christie R Eheman; Elizabeth M Ward Journal: Cancer Date: 2013-12-16 Impact factor: 6.860
Authors: Dariga S Smailova; Elisa Fabbro; Serik E Ibrayev; Luca Brusati; Yuliya M Semenova; Umutzhan S Samarova; Farida S Rakhimzhanova; Sabit M Zhussupov; Zaituna A Khismetova; Hengameh Hosseini Journal: Prostate Cancer Date: 2020-01-27